Please ensure Javascript is enabled for purposes of website accessibility

Biogen Buys Azheimer's and Parkinson's Drug From Pfizer

By Jim Crumly - Jan 13, 2020 at 4:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The early-stage drug is part of Biogen's push into neurological diseases.

Biogen (BIIB 0.42%) announced it has reached an agreement with Pfizer (PFE -0.76%) to buy a drug in early development that is designed to treat debilitating symptoms related to the disruption of daily rhythms in patients with Alzheimer's and Parkinson's disease. The pipeline drug, PF-05251749, is for the treatment of Sundowning, a condition affecting 20% of Alzheimer's patients that causes confusion and anxiety late in the day, and Irregular Sleep Wake Rhythm Disorder, which causes fragmented nighttime sleep in Parkinson's sufferers.

Biogen will pay $75 million up front for rights to the drug, up to $635 million in additional milestone payments as it develops and commercializes it, and tiered royalties on sales from high single digits to the low teens.

Brain scan images on a display screen.

Image source: Getty Images.

Pfizer spun off its drug candidates for central nervous system (CNS) disorders in 2018 to create Cerevel Therapeutics, jointly owned with Bain Capital, but PF-05251749 apparently didn't make the cut and was put up for sale at a low price. The drug was evaluated before the spin-off in two Phase 1A clinical trials that yielded positive safety results but no data on efficacy.

Biogen intends to initiate a phase 2B study of PF-05251749 in the fourth quarter of 2020 as part of its effort to grow its assets in CNS drugs. In October, Biogen stunned investors when it reversed itself on Alzheimer's drug aducanumab, saying it will file for approval of the drug with the U.S. Food and Drug Administration in early 2020 after having given up on it earlier in 2019. The biotech company also has another Alzheimer's drug, BAN2401, in late stage testing that uses an approach similar to that of aducanumab.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$205.07 (0.42%) $0.85
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.58 (-0.76%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.